The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability

References

• Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312–334. .
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618–621.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Renard J-P, Nordmann J-P, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2012;23(1):47–54. .
   Web of Science ®Google Scholar
• Lemij HG, Hoevenaars JG, van der Windt C, et al. Patient satisfaction with glaucoma therapy: reality or myth? Clin Ophthalmol. 2015;9:785–793.
   PubMed Web of Science ®Google Scholar
• Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol. 2009;147(725–735.e1):725–735.e1. .
   PubMedGoogle Scholar
• Labbé A, Terry O, Brasnu E, et al. Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea. 2012;31(9):994–999.
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88(3):329–336. .
   PubMed Web of Science ®Google Scholar
• Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013;22(9):730–735.
   PubMed Web of Science ®Google Scholar
• Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther. 2008;25(8):743–751.
   PubMed Web of Science ®Google Scholar
• Pauly A, Meloni M, Brignole-Baudouin F, et al. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci. 2009;50(4):1644–1652.
   PubMed Web of Science ®Google Scholar
• Brignole-Baudouin F, Desbenoit N, Hamm G, et al. A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits. PLoS ONE. 2012;7:e50180.
   PubMed Web of Science ®Google Scholar
• Stahlberg C. E, Pfeiffer N. Patient-reported nonadherence with glaucoma therapy. J Ocul Pharmacol Ther. 2019;35(4):223–228.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Schmetterer L, Costa VP, et al. Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review. Expert Opin Drug Saf. 2020 Sep 29:1–16. Online ahead of print. 10.1080/14740338.2020.1826928
   Web of Science ®Google Scholar
• Smedowski A, Paterno JJ, Toropainen E, et al. Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells. J Biochem Pharmacol Res. 2014;2(4):175–184.
   PubMedGoogle Scholar
• Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Exp Rev Ophthalmol. 2009;4(1):59–64.
   Google Scholar
• Konstas AGP, Holló G. Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma. Expert Opin Pharmacother. 2016;17(9):1271–1283.
   PubMed Web of Science ®Google Scholar
• Champeau E, Edelhauser H. Effect of ophthalmic preservatives on the ocular surface: conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine digluconate. In: Holly F, Lamberts D, MacKeen D, editors. The preocular tear film in health, disease, and contact lens wear. Lubbock, TX: Dry Eye Institute; 1986. p. 292–302.
   Google Scholar
• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276–283. .
   PubMed Web of Science ®Google Scholar
• Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17(3):341–349.
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–355.
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418–423.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013;11:246–258.
   Google Scholar
• Herreras JM, Pastor JC, Calonge M, et al. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology. 1992;99(7):1082–1088.
   PubMed Web of Science ®Google Scholar
• Banitt M, Jung H. Ocular surface disease in the glaucoma patient. Int Ophthalmol Clin. 2018;58(3):23–33.
   PubMedGoogle Scholar
• Sherwood MB, Grierson I, Millar L, et al. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology. 1989;96(3):327–335.
   PubMed Web of Science ®Google Scholar
• Holló G, Katsanos A, Boboridis KG, et al. Preservative-free prostaglandin analogs and prostaglandin/timolol fixed combinations in the treatment of glaucoma: efficacy, safety and potential advantages. Drugs. 2018;78:39–64.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008;115(1):109–115. .
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153(1):1–9.e2.
   PubMed Web of Science ®Google Scholar
• Rossi GC, Pasinetti GM, Scudeller L, et al. Ocular surface disease and glaucoma: how to evaluate impact on quality of life. J Ocul Pharmacol Ther. 2013;29(4):390–394.
   PubMed Web of Science ®Google Scholar
• Abegão Pinto L, Vandewalle E, Gerlier L, et al. Cosopt UD switch study group. improvement in glaucoma patient quality of life by therapy switch to preservative-free timolol/dorzolamide fixed combination. Ophthalmologica. 2014;231(3):166–171.
   PubMed Web of Science ®Google Scholar
• Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(Suppl 1):S57–68.
   PubMed Web of Science ®Google Scholar
• Stryker JE, Beck AD, Primo SA, et al. An exploratory study of factors influencing glaucoma treatment adherence. J Glaucoma. 2010;19(1):66–72. .
   PubMed Web of Science ®Google Scholar
• Broadway DC, Grierson I, O’Brien C, et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112:1446–1454.
   PubMed Web of Science ®Google Scholar
• Ammar DA, Kahook MY. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis. 2011;17:1806–1813.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Denoyer A, Desbenoit N, et al. In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2012;110:40–63.
   PubMedGoogle Scholar
• Bouchemi M, Roubeix C, Kessal K, et al. Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma. Toxicol In Vitro. 2017;41:21–29.
   PubMed Web of Science ®Google Scholar
• Batra R, Tailor R, Mohamed S. Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control. J Glaucoma. 2014;23(1):56–60.
   PubMed Web of Science ®Google Scholar
• Dubrulle P, Labbe A, Brasnu E, et al., Influence of treating ocular surface disease on intraocular pressure in glaucoma patients intolerant to their topical treatments: a report of 10 cases. J Glaucoma. 27(12): 1105–1111. 2018. .
   PubMed Web of Science ®Google Scholar
• Mylla Boso AL, Gasperi E, Fernandes L, et al. Impact of ocular surface disease treatment in patients with glaucoma. Clin Ophthalmol. 2020;14:103–111.
   PubMed Web of Science ®Google Scholar
• Thygesen J. Glaucoma therapy: preservative-free for all? Clin Ophthalmol. 2018;12:707–717.
   PubMed Web of Science ®Google Scholar
• Saini M, Dhiman R, Dada T, et al. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications. Eye (Lond). 2015;29(6):808–814.
   PubMed Web of Science ®Google Scholar
• Boboridis KG, Konstas AGP. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease. Expert Opin Pharmacother. 2018;19(9):1027–1039.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Baudouin C. Challenges in the clinical measurement of ocular surface disease in glaucoma patients. Clin Ophthalmol. 2011;5:1575–1583.
   PubMedGoogle Scholar
• Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology. 1984;91(6):564–579.
   PubMed Web of Science ®Google Scholar
• Miyake K, Ibaraki N, Goto Y, et al. ESCRS Binkhorst lecture 2002: pseudophakic preservative maculopathy. J Cataract Refract Surg. 2003;29(9):1800–1810.
   PubMed Web of Science ®Google Scholar
• Stevens AM, Kestelyn PA, De Bacquer D, et al. Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: a randomized clinical trial. Acta Ophthalmol. 2012;90(3):e221–224.
   PubMed Web of Science ®Google Scholar
• Hamard P, Blondin C, Debbasch C, et al. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol. 2003;241(12):1037–1043.
   PubMed Web of Science ®Google Scholar
• Yu AL, Birke K, Moriniere J, et al. TGF-{beta}2 induces senescence-associated changes in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2010;51(11):5718–5723.
   PubMed Web of Science ®Google Scholar
• Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6(1):45–52.
   PubMed Web of Science ®Google Scholar
• Cracknell KPB, Grierson I. Prostaglandin analogues in the anterior eye: their pressure lowering action and side effects. Exp Eye Res. 2009;88(4):786–791.
   PubMed Web of Science ®Google Scholar
• Dams I, Wasyluk J, Prost M, et al. Therapeutic uses of prostaglandin F(2α) analogues in ocular disease and novel synthetic strategies. Prostaglandins Other Lipid Mediat. 2013;104–105:109–121.
   PubMed Web of Science ®Google Scholar
• Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53(Suppl 1):S93–105.
   PubMed Web of Science ®Google Scholar
• Rouland J-F, Traverso CE, Stalmans I, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013;97(2):196–200. .
   PubMed Web of Science ®Google Scholar
• Misiuk-Hojlo M, Pomorska M, Mulak M, et al. The RELIEF study: tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension. Eur J Ophthalmol. 2019;29(2):210–215. .
   PubMed Web of Science ®Google Scholar
• El Ameen A, Vandermeer G, Khanna RK, et al. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues. Eur J Ophthalmol. 2019;29(6):645–653.
   PubMed Web of Science ®Google Scholar
• Pillunat LE, Eschstruth P, Häsemeyer S, et al. Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice. Clin Ophthalmol. 2016;10:1759–1765.
   PubMed Web of Science ®Google Scholar
• Day DG, Walters TR, Schwartz GF, et al. Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br J Ophthalmol. 2013;97(8):989–993.
   PubMed Web of Science ®Google Scholar
• Swymer C, Neville MW. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2012;46(11):1506–1510.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Boboridis KG, Kapis P, et al. 24-Hour efficacy and ocular surface health with preservative-free tafluprost alone and in conjunction with preservative-free dorzolamide/timolol fixed combination in open-angle glaucoma patients insufficiently controlled with preserved latanoprost monotherapy. Adv Ther. 2017;34(1):221–235.
   PubMed Web of Science ®Google Scholar
• Rossi GCM, Scudeller L, Lumini C, et al. An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy. Sci Rep. 2019;9(1):4282.
   PubMedGoogle Scholar
• Sneader W. Alkaloids. In : Drug discovery: a history. 1st edition. Chichester (West Sussex): John Wiley & Sons. 2005. 98
   Google Scholar
• Krieglstein K, Schrems W, De Natale R. The comparative ocular responses of pilocarpine ophthalmic rods and pilocarpine eye drops. In: European Glaucoma Society, editor. 2nd EGS meeting. Helsinki: Finland; 1984. p. 97–103.
   Google Scholar
• Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. Br J Ophthalmol. 2018;102(11):1497–1503.
   PubMedGoogle Scholar
• Gómez-Aguayo F, Paczka JA, Leñero-Córdova R, et al. A phase III randomized clinical trial of a 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide fixed combination, preservative-free ophthalmic solution vs. 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide fixed combination in patients with controlled primary open-angle glaucoma. Ophthalmol Ther. 2018;7(1):145–156. .
   PubMedGoogle Scholar
• Rolle T, Curto D, Alovisi C, et al. Timogel® vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance. Eur J Ophthalmol. 2012;22(1):28–33.
   PubMed Web of Science ®Google Scholar
• Duru Z, Ozsaygili C. Preservative-free versus preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages. Cutan Ocul Toxicol. 2020;39(1):21–24.
   PubMed Web of Science ®Google Scholar
• Hedengran A, Steensberg AT, Virgili G, et al. Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis. Br J Ophthalmol. 2020 Feb 12;2019-315623. E-Pub. DOI:10.1136/bjophthalmol-2019-315623
   Web of Science ®Google Scholar
• Wilson FM. Adverse external ocular effects of topical ophthalmic medications. Surv Ophthalmol. 1979;24(2):57–88.
   PubMed Web of Science ®Google Scholar
• Pellinen P, Huhtala A, Tolonen A, et al. The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo. Curr Eye Res. 2012;37(2):145–154.
   PubMed Web of Science ®Google Scholar
• Iester M, Telani S, Frezzotti P, et al. Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers. J Ocul Pharmacol Ther. 2014;30(6):476–481. .
   PubMed Web of Science ®Google Scholar
• Nordmann J-P, Auzanneau N, Ricard S, et al. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes. 2003;1(1):75.
   PubMedGoogle Scholar
• Loon SC, Jin J, Jin Goh M. The relationship between quality of life and adherence to medication in glaucoma patients in Singapore. J Glaucoma. 2015;24(5):e36–42.
   PubMed Web of Science ®Google Scholar
• European Glaucoma Society.Terminology and guidelines for glaucoma.4thedition. Savona, Italy: Publi Comm, 2014. p. 131-191.
   Google Scholar
• Conlon R, Saheb H, Ahmed IIK. Glaucoma treatment trends: a review. Can J Ophthalmol. 2017;52(1):114–124.
   PubMed Web of Science ®Google Scholar
• Holló G, Vuorinen J, Tuominen J, et al. Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014;31(9):932–944.
   PubMed Web of Science ®Google Scholar
• Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed travoprost 0.004%/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. 2017;176:61–69.
   PubMed Web of Science ®Google Scholar
• Holló G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014;15(12):1737–1747.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Quaranta L, Bozkurt B, et al. 24-h efficacy of glaucoma treatment options. Adv Ther. 2016;33(4):481–517. .
   PubMed Web of Science ®Google Scholar
• Konstas AG, Kahook MY, Araie M, et al. Diurnal and 24-h intraocular pressures in glaucoma: monitoring strategies and impact on prognosis and treatment. Adv Ther. 2018;35(11):1775–1804. .
   PubMed Web of Science ®Google Scholar
• Paimela T, Ryhänen T, Kauppinen A, et al. The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells. Mol Vis. 2012;18:1189–1196.
   PubMed Web of Science ®Google Scholar
• Goldberg I, Gil Pina R, Lanzagorta-Aresti A, et al. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. Br J Ophthalmol. 2014;98(7):926–931.
   PubMed Web of Science ®Google Scholar
• Aptel F, Pfeiffer N, Schmickler S, et al. Noninferiority of preservative-free versus BAK-preserved latanoprost-timolol fixed combination eye drops in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2019;28(6):498–506. .
   PubMed Web of Science ®Google Scholar
• Bourne RRA, Kaarniranta K, Lorenz K, et al. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study. BMJ Open. 2019;9(4):e024129.
   PubMed Web of Science ®Google Scholar
• Abe RY, Zacchia RS, Santana PR, et al. Effects of benzalkonium chloride on the blood-aqueous and blood-retinal barriers of pseudophakic eyes. J Ocul Pharmacol Ther. 2014;30(5):413–418.
   PubMed Web of Science ®Google Scholar
• Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002;47(Suppl 1):S203–218.
   PubMed Web of Science ®Google Scholar
• Holló G, Aung T, Cantor LB, et al. Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: mechanism, diagnosis, and management. Surv Ophthalmol. 2020;65(5):496–512.
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Egorov E, Kaarniranta K, et al. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. Clin Ophthalmol. 2016;10:445–454.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Katsanos A, Athanasopoulos GP, et al. Preservative-free tafluprost/timolol fixed combination: comparative 24-h efficacy administered morning or evening in open-angle glaucoma patients. Expert Opin Pharmacother. 2018;19(18):1981–1988. .
   PubMed Web of Science ®Google Scholar
• Oddone F, Tanga L, Kóthy P, et al., VISIONARY Study Group. Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: the VISIONARY study. Adv Ther. 2020;37(4):1436–1451. .
   PubMed Web of Science ®Google Scholar
• Takagi Y, Osaki H, Yamashita T, et al. Prospective observational post-marketing study of tafluprost 0.0015%/timolol 0.5% combination ophthalmic solution for glaucoma and ocular hypertension: short-term efficacy and safety. Ophthalmol Ther. 2016;5(2):191–206.
   PubMed Web of Science ®Google Scholar
• Ayaki M, Iwasawa A, Niwano Y. Cell viability score as an integrated indicator for cytotoxicity of benzalkonium chloride-containing antiglaucoma eyedrops. Biocontrol Sci. 2012;17(3):121–128.
   PubMed Web of Science ®Google Scholar
• Hutzelmann J, Owens S, Shedden A, et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol. 1998;82(11):1249–1253.
   PubMed Web of Science ®Google Scholar
• Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105:1945–1951.
   PubMed Web of Science ®Google Scholar
• Clineschmidt CM, Williams RD, Snyder E, et al. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology. 1998;105:1952–1959.
   PubMed Web of Science ®Google Scholar
• Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105:1936–1944.
   PubMed Web of Science ®Google Scholar
• Shedden A, Adamsons IA, Getson AJ, et al. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPTTM) in patients with elevated intraocular pressure in a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2010;248(12):1757–1764. .
   PubMed Web of Science ®Google Scholar
• Nemera. Novelia (R). Using intelligent design to deliver safe preservative free multi-dose eye drops. [cited 2021 Jan 18]. Available from: https://www.nemera.net/wp-content/uploads/2014/06/WP-Novelia-alternativetofilters-June 2015. pdf.
   Google Scholar
• GmbH URSATEC primary packaging with non-airless 3K® pump system technology [Internet]. [cited 2020 Mar 27]. Available from: https://www.ursatec.com/en/products/technology/3kr/
   Google Scholar
• Denis P, Duch S, Chen E, et al. European real-world data about the use of a new delivery system containing a preservative-free multi-dose glaucoma treatment. Eur J Ophthalmol. 2020;112067212091934. Online ahead of print. doi:10.1177/1120672120919342
   Web of Science ®Google Scholar
• Renieri G, Führer K, Scheithe K, et al. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients. J Ocul Pharmacol Ther. 2010;26(6):597–603.
   PubMed Web of Science ®Google Scholar
• Hutnik C, Neima D, Ibrahim F, et al. Tolerability and effectiveness of preservative-free dorzolamide-timolol (preservative-free COSOPT) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2010;4:581–590.
   PubMedGoogle Scholar
• Floriani I, Quaranta L, Rulli E, et al. Health-related quality of life in patients with primary open-angle glaucoma. An Italian multicentre observational study. Acta Ophthalmol. 2016;94(5):e278–86.
   PubMed Web of Science ®Google Scholar
• Kaarniranta K, Ropo A. Preferences and ease of use of preservative-free IOP-lowering eye drop containers: a comparison of two multi-dose bottles. Clin Invest (Lond). 2018;8:1.
   Google Scholar
• Lavin MJ, Wormald RP, Migdal CS, et al. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990;108(11):1543–1548.
   PubMedGoogle Scholar
• Longstaff S, Wormald RP, Mazover A, et al. Glaucoma triple procedures: efficacy of intraocular pressure control and visual outcome. Ophthalmic Surg. 1990;21(11):786–793.
   PubMedGoogle Scholar
• Hong S, Lee CS, Seo KY, et al. Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am J Ophthalmol. 2006;142(1):185–186.
   PubMed Web of Science ®Google Scholar
• Garcia-Feijoo J, Sampaolesi JR. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin Ophthalmol. 2012;6:441–446.
   PubMedGoogle Scholar
• Pérez-Bartolomé F, Martínez-de-la-Casa JM, Arriola-Villalobos P, et al. Ocular surface disease in patients under topical treatment for glaucoma. Eur J Ophthalmol. 2017;27(6):694–704.
   PubMed Web of Science ®Google Scholar
• Pérez Bartolomé F, Martínez de la Casa JM, Arriola VP, et al. Ocular redness measured with the keratograph 5m in patients using anti-glaucoma eye drops. Semin Ophthalmol. 2018;33(5):643–650.
   PubMed Web of Science ®Google Scholar
• Labbé A, Pauly A, Liang H, et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther. 2006;22(4):267–278.
   PubMed Web of Science ®Google Scholar
• García-Feijoo J, Muñoz-Negrete FJ, Hubatsch DA, et al. Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost. Clin Ophthalmol. 2016;10:2085–2091.
   PubMed Web of Science ®Google Scholar
• Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16(1):98–103.
   PubMed Web of Science ®Google Scholar
• Lopes JF, Hubatsch DA, Amaris P. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study. BMC Ophthalmol. 2015;15(1):166.
   PubMedGoogle Scholar
• Hong S, Han S-H, Kim CY, et al. Brimonidine reduces TGF-beta-induced extracellular matrix synthesis in human Tenon’s fibroblasts. BMC Ophthalmol. 2015;15(1):54.
   PubMedGoogle Scholar
• Doğan AS, Orhan M, Söylemezoğlu F, et al. Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin Experiment Ophthalmol. 2004;32(1):62–66.
   PubMed Web of Science ®Google Scholar
• Martinez-de-la-Casa JM, Perez-Bartolome F, Urcelay E, et al. Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost. Ocul Surf. 2017;15(4):723–729.
   PubMed Web of Science ®Google Scholar
• Schwab IR, Linberg JV, Gioia VM, et al. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology. 1992;99(2):197–202.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Nordmann J-P, Denis P, et al. Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Graefes Arch Clin Exp Ophthalmol. 2002;240(11):929–935.
   PubMed Web of Science ®Google Scholar
• Broadway DC, Grierson I, Stürmer J, et al. Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch Ophthalmol. 1996;114(3):262–267.
   PubMedGoogle Scholar
• Breusegem C, Spielberg L, Van Ginderdeuren R, et al. Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmology. 2010;117(7):1324–1330.
   PubMed Web of Science ®Google Scholar
• Lorenz K, Wasielica-Poslednik J, Bell K, et al. Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma. PLoS ONE. 2017;12(2):e0171636.
   PubMed Web of Science ®Google Scholar
• Roberti G, Oddone F, Agnifili L, et al. Steroid-induced glaucoma: epidemiology, pathophysiology, and clinical management. Surv Ophthalmol. 2020;65(4):458–472.
   PubMed Web of Science ®Google Scholar
• Zhang X, Vadoothker S, Munir WM, et al. Ocular surface disease and glaucoma medications: a clinical approach. Eye Contact Lens. 2019;45(1):11–18.
   PubMed Web of Science ®Google Scholar
• Chamard C, Larrieu S, Baudouin C, et al. Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016. Acta Ophthalmol. 2020 Mar 31;98(7):e876-e881.
   PubMed Web of Science ®Google Scholar
• Figus M, Agnifili L, Lanzini M, et al. Topical preservative-free ophthalmic treatments: an unmet clinical need. Expert Opin Drug Deliv. 2020 Dec 16:1-18. doi: 10.1080/17425247.2021.1860014. Online ahead of print.
   Google Scholar